UPM Pharmaceuticals Appoints Dr. Chi-Chang Wung as Director of Analytical Development

BRISTOL, Tenn., Aug. 29, 2018 /PRNewswire/ -- UPM Pharmaceuticals, a Contract Development and Manufacturing Organization (CDMO) focused on oral solid and semi-solid drug dosage forms, has appointed Dr. Chi-Chang Wung to the position of Director of Analytical Development. Dr. Wung will oversee UPM's analytical development group.

Daniel Dixon, VP of Quality Control for UPM, said, "Dr. Wung brings a tremendous amount of experience and knowledge to this key position at UPM. With his diverse experience in analytical development, pharmaceutical development and quality operations, I am confident that Dr. Wung will bring a wealth of knowledge to this pivotal position and provide solid leadership to the analytical development group."

Dr. Wung brings more than 20 years of experience in analytical development, pharmaceutical development, quality operations and CMC consulting to his role at UPM. Previously, he served in senior analytical development and quality control positions at Alkermes, SIGA Technologies and Asymchem Laboratories.

Jim Gregory, CEO of UPM, said, "With decades of experience in analytical development as well as the management of systems and regulatory practices, Dr. Wung brings significant industry expertise and leadership skills to our analytical development group. We are confident that under his direction, the team will rise to new levels of excellence."

"I am excited to be a part of this departmental growth at UPM," said Dr. Wung. "A strong analytical development group is paramount for a CDMO to be successful. My goals are to lead from a quality by design approach, while mentoring my group to strive for excellence within the analytical organization at UPM."

About UPM Pharmaceuticals
UPM Pharmaceuticals, Inc. is an independent drug development and contract manufacturer serving the pharmaceutical and biotechnology industries. We provide high quality drug development services including custom formulation development, cGMP clinical and commercial manufacturing, analytical methods services, and stability testing. UPM's clients enjoy service that is customized and fast with total quality management characteristics of a customer focused business. Our history includes successful collaborative interactions with small virtual and large billion dollar companies providing customized product development services and solutions. UPM focuses on drug development for dosages with oral routes of administration, in solid dosage forms such as capsules and tablets, and semi-solid creams and ointments. Our 475,000 square foot commercial manufacturing facility based in Bristol, Tennessee allows us to serve our clients' needs from early stage development to large scale commercial production. More at www.upm-inc.com

For more information:

Mary Lee Schiesz
Manager of Marketing
Email: [email protected]
Phone: +1 (423) 989-7057

SOURCE UPM Pharmaceuticals, Inc.